Mayne Pharma
Kim joined Mayne Pharma in May 2022 and has more than 20 years of experience covering commercial and IP law, most of which were spent working in the pharmaceutical industry. Prior to joining Mayne Pharma, Kim was Vice President, Business Development Counsel at Alkermes, Inc. Previously, she worked for Novartis for 12 years and at GSK, General Electric and Alston & Bird focusing primarily in the areas of intellectual property, corporate development and patent law. Kim has a BA in Chemistry and BS in Zoology from North Carolina State University. She earned her Juris Doctorate from North Carolina Central University School of Law and is also a registered US Patent Attorney.
This person is not in any offices
Mayne Pharma
1 followers
Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing branded and generic pharmaceuticals. It operates through four segments: Generic Products (GPD), Specialty Brands (SBD), Metrics Contract Services (MCS) and Mayne Pharma International (MPI). The GPD segment is engaged in the manufacture and distribution of generic pharmaceutical products in the United States. The SBD segment markets and distributes specialty branded pharmaceutical products in the United States. The MCS segment is engaged in the provision of contract analytical and pharmaceutical development services to third-party customers in the United States. The MPI segment is engaged in Australian manufacture and sale of branded and generic pharmaceutical product globally and provision of contract manufacturing services to third-party customers within Australia.